Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

October 6, 2017: By Joan McKenna
Alcon's AutonoMe

Alcon’s AutonoMe

Alcon’s AutonoMe preloaded intraocular lens delivery system for its Clareon IOL has gained CE mark approval, parent Novartis announced Oct. 6.

The new device will be introduced with the Clareon IOL at the 2017 meeting of the European Society of Cataract and Refractive Surgeons in Lisbon, Portugal.

“Throughout Alcon’s history, we have worked with doctors to enhance and transform the way cataract surgery is performed,” said Mike Ball, chief executive officer of Alcon, in Fort Worth Texas. “Clareon AutonoMe builds upon the comprehensive legacy of AcrySof by offering cataract surgeons easy, intuitive control of IOL delivery with the newest optic material.”

Features of the AutonoMe include an automated CO2-powered delivery mechanism and an intuitive, ergonomic design to allow precise and simplified single-handed control of IOL placement during cataract surgery, Switzerland-based Novartis said.

The Clareon hydrophobic acrylic IOL, made of a new biomaterial designed to provide sharp vision and optical clarity, received CE mark approval in May.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales